Board of Directors
InvestorsInvestors
Nitec raised US$ 10m (2004), CHF 32 million (2007) and more recently CHF 24 million (2008) in three fundraising rounds. In addition to the two co-founders, the major shareholders of Nitec Pharma are:
24/10/2007
Nitec Pharma to present 12-month efficacy and safety data for Lodotra™ at the annual meeting of the American College of Rheumatology in San Francisco
more
Nitec Pharma to present 12-month efficacy and safety data for Lodotra™ at the annual meeting of the American College of Rheumatology in San Francisco
more
12/06/2008
Nitec to present Lodotra™ 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR) in Paris.
more
Nitec to present Lodotra™ 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR) in Paris.
more
22/01/2008
Nitec’s phase 3 results with Lodotra™ in RA published in current issue of The Lancet.
more
Nitec’s phase 3 results with Lodotra™ in RA published in current issue of The Lancet.
more
